
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Abametapir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Pelthos Therapeutics
Deal Size : $1.8 million
Deal Type : Acquisition
Pelthos Therapeutics Acquires Xeglyze® Topical Treatment for Head Lice
Details : Through the acquisition of Abametapir, targeting MMPs, the deal aims to advance treatments for head lice infestation.
Product Name : Xeglyze
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 05, 2026
Lead Product(s) : Abametapir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Pelthos Therapeutics
Deal Size : $1.8 million
Deal Type : Acquisition
